Who
Andrew C. Von Eschenbach
Director
Company insider
Files Form 4 as: Director, Bausch + Lomb; Director, TriSalus Life Sciences; Director, Celularity; Director, Radius Health; Director, Bausch Health Companies; Director, Asterias Biotherapeutics; Director, Lineage Cell Therapeutics.
In numbers
- Trades disclosed
- 43
- Buys
- 5
- Sells
- 2
- Bought
- $247K
- Sold
- $613K
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 1 Jul 2012
- Last trade
- 7 Aug 2026
- Last filed
- 10 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 10 Aug 2026 | BLCO Bausch + LombMedical Devices | SEC FORM 4 Sold | $100K6,059 at $16.58 | filing |
| 7 Aug 2026filed 10 Aug 2026 | BLCO Bausch + LombMedical Devices | SEC FORM 4 Sold | $100K6,059 at $16.58 | filing |
| 6 Aug 2026filed 10 Aug 2026 | BLCO Bausch + LombMedical Devices | SEC FORM 4 Sold | $206K12,500 at $16.50 | filing |
| 6 Aug 2026filed 10 Aug 2026 | BLCO Bausch + LombMedical Devices | SEC FORM 4 Sold | $206K12,500 at $16.50 | filing |
| 26 May 2026filed 28 May 2026 | BLCO Bausch + LombMedical Devices | SEC FORM 4 Code A | $250K15,842 at $15.78 | filing |
| 26 May 2026filed 28 May 2026 | BLCO Bausch + LombMedical Devices | SEC FORM 4 Code A | $250K15,842 at $15.78 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BLCO Bausch + LombMedical Devices | SEC FORM 4 Bought | $80K4,364 at $18.31 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BLCO Bausch + LombMedical Devices | SEC FORM 4 Code A | —4,364 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BLCO Bausch + LombMedical Devices | SEC FORM 4 Bought | $80K4,364 at $18.31 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BLCO Bausch + LombMedical Devices | SEC FORM 4 Code A | —4,364 at $0.00 | filing |
| 27 May 2025filed 28 May 2025 | BLCO Bausch + LombMedical Devices | SEC FORM 4 Code A | —20,338 at $0.00 | filing |
| 2 May 2025filed 6 May 2025 | BLCO Bausch + LombMedical Devices | SEC FORM 4 Bought | $20K1,695 at $11.76 | filing |
| 13 Aug 2024filed 21 Aug 2024 | TLSI TriSalus Life Sciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 2 Aug 2024filed 6 Aug 2024 | BLCO Bausch + LombMedical Devices | SEC FORM 4 Code A | —14,696 at $0.00 | filing |
| 3 Jun 2024filed 5 Jun 2024 | TLSI TriSalus Life Sciencesoption or derivative · Medical Devices | SEC FORM 4 Code G | —35,000 at $0.00 | filing |
| 3 Jun 2024filed 5 Jun 2024 | TLSI TriSalus Life Sciencesoption or derivative · Medical Devices | SEC FORM 4 Code G | —35,000 at $0.00 | filing |
| 10 Aug 2023filed 14 Aug 2023 | TLSI TriSalus Life Sciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | CELU Celularityoption or derivative · Biotechnology | SEC FORM 4 Code A | —277,778 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | CELU CelularityBiotechnology | SEC FORM 4 Code A | —199,921 at $0.00 | filing |
| 4 May 2023filed 5 May 2023 | BLCO Bausch + LombMedical Devices | SEC FORM 4 Code A | —12,857 at $0.00 | filing |
News
Verily Health, Bausch + Lomb partner to bring dry eye care to appBLCO · healio.com · 15 Oct 2026Bausch + Lomb (NYSE:BLCO) Stock Price Down 5.8% – Here's What HappenedBLCO · dailypolitical.com · 14 Oct 2026
0 headlines in the last 90 days name Andrew C. Von Eschenbach; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.